Treatment outcomes following continuous miglustat therapy in
Por um escritor misterioso
Last updated 14 julho 2024
![Treatment outcomes following continuous miglustat therapy in](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13023-020-01363-2/MediaObjects/13023_2020_1363_Fig1_HTML.png)
Background Niemann-Pick disease Type C (NP-C) is a rare, progressive neurodegenerative disorder characterized by progressive neurodegeneration and premature death. We report data at closure of the NPC Registry that describes the natural history, disease course and treatment experience of NP-C patients in a real-world setting. Methods The NPC Registry was a prospective observational cohort study that ran between September 2009 and October 2017. Patients with a confirmed diagnosis of NP-C were enrolled regardless of treatment status. All patients underwent clinical assessments and medical care as determined by their physicians; data were collected through a secure internet-based portal. Results At closure on October 19, 2017, 472 patients from 22 countries were enrolled in the NPC Registry. Mean (standard deviation) age at enrollment was 21.2 (15.0) years, and 51.9% of patients were male. First neurological symptom onset occurred during the early-infantile (< 2 years), late-infantile (2 to < 6 years), juvenile (6 to < 15 years), or adolescent/adult (≥ 15 years) periods in 13.5, 25.6, 31.8, and 29.1% of cases, respectively. The most frequent neurological manifestations prior to enrollment included ataxia (67.9%), vertical supranuclear gaze palsy (67.4%), dysarthria (64.7%), cognitive impairment (62.7%), dysphagia (49.1%), and dystonia (40.2%). During infancy, splenomegaly and hepatomegaly were frequent (n = 199/398 [50%] and n = 147/397 [37.0%], respectively) and persisted in most affected patients. Of the 472 enrolled patients, 241 were continuously treated with miglustat during the NPC Registry observation period, of whom 172 of these 241 patients were treated continuously for ≥12 months. A composite disability score that assesses impairment of ambulation, manipulation, language, and swallowing was highest in the early-infantile population and lowest in the adolescent/adult population. Among the continuous miglustat therapy population, 70.5% of patients had improved or had stable disease (at least 3 of the 4 domains having a decreased or unchanged score between enrollment and last follow-up). The NPC Registry did not identify any new safety signals associated with miglustat therapy. Conclusions The profiles of clinical manifestations in the final NPC Registry dataset agreed with previous clinical descriptions. Miglustat therapy was associated with a stabilization of neurological manifestations in most patients. The safety and tolerability of miglustat therapy was consistent with previous reports.
![Treatment outcomes following continuous miglustat therapy in](https://www.frontiersin.org/files/Articles/906647/fphar-13-906647-HTML/image_m/fphar-13-906647-g002.jpg)
Frontiers Therapeutic Strategies For Tay-Sachs Disease
![Treatment outcomes following continuous miglustat therapy in](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41525-023-00365-w/MediaObjects/41525_2023_365_Fig1_HTML.png)
Understanding the phenotypic variability in Niemann-Pick disease
![Treatment outcomes following continuous miglustat therapy in](https://thejns.org/focus/cover/journals/neurosurg-focus/24/3-4/cover.jpg)
Central nervous system therapy for lysosomal storage disorders in
![Treatment outcomes following continuous miglustat therapy in](https://www.thelancet.com/cms/attachment/63376b9e-f4e3-4d29-ab9f-f0852d90a33f/gr1.gif)
Safety and efficacy of cipaglucosidase alfa plus miglustat versus
![Treatment outcomes following continuous miglustat therapy in](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13023-018-0844-0/MediaObjects/13023_2018_844_Fig1_HTML.png)
Miglustat in Niemann-Pick disease type C patients: a review
![Treatment outcomes following continuous miglustat therapy in](https://ars.els-cdn.com/content/image/1-s2.0-S1096719221007411-gr1.jpg)
Estimating the prevalence of Niemann-Pick disease type C (NPC) in
![Treatment outcomes following continuous miglustat therapy in](https://onlinelibrary.wiley.com/cms/asset/7af3b415-c677-499d-8560-254216c2b4e0/dmcn14869-fig-0001-m.jpg)
Precision medicine for genetic childhood movement disorders - Soo
![Treatment outcomes following continuous miglustat therapy in](https://www.neurology.org/cms/asset/2c9588bf-303b-4521-b493-0de7b86f1582/wnl.2019.93.issue-19.largecover.jpg)
Large variation in effects during 10 years of enzyme therapy in
![Treatment outcomes following continuous miglustat therapy in](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13023-020-01363-2/MediaObjects/13023_2020_1363_Fig3_HTML.png)
Treatment outcomes following continuous miglustat therapy in
![Treatment outcomes following continuous miglustat therapy in](https://pub.mdpi-res.com/ijms/ijms-17-01065/article_deploy/html/images/ijms-17-01065-ag.png?1581070364)
IJMS, Free Full-Text
![Treatment outcomes following continuous miglustat therapy in](https://www.cell.com/cms/attachment/24a82268-e661-4130-b29d-41eab359aaac/fx1_lrg.jpg)
Therapeutic advantages of combined gene/cell therapy strategies in
Recomendado para você
-
IJMS, Free Full-Text14 julho 2024
-
Rare Diseases Research: Clinical Trial for Niemann-Pick Type C14 julho 2024
-
Potential treatment for Niemann-Pick type C, a rare neurodegenerative disease14 julho 2024
-
NNPDF on X: October is Global Niemann-Pick Disease Awareness Month! For more information on Niemann-Pick Disease or to make a donation to NNPDF go to #niemannpick #ASMD #NPC #raredisease #NNPDF #NiemannPickC14 julho 2024
-
National Niemann-Pick Disease Foundation, Inc. - October is14 julho 2024
-
Niemann–Pick type C disease: cellular pathology and14 julho 2024
-
Fig 2. Subcortical Volumetric Reductions in Adult Niemann-Pick14 julho 2024
-
The Neuropsychiatry of Niemann-Pick Type C Disease in Adulthood14 julho 2024
-
Niemann-Pick disease type-B: a unique case report with compound14 julho 2024
-
Signatures of natural selection and ethnic-specific prevalence of14 julho 2024
você pode gostar
-
Dubrasil - Central de Dublagem - O dublador responsável pela voz14 julho 2024
-
Door Hanger Envelopes14 julho 2024
-
Sonic Speed Simulator News & Leaks! 🎃 on X: NEW: 'Sonic' and 'Classic Knuckles' in icons for #SonicSpeedSimulator on #Roblox. Are you excited? Let me know below 👇🏻 / X14 julho 2024
-
Racha Cuca - Problemas de Lógica - Amigo Secreto14 julho 2024
-
MORENA SERENA Morena serena do olhar Nivaldo Joaquim - Pensador14 julho 2024
-
Maybe the Lack of Message in The Last of Us Part II Is the Point14 julho 2024
-
FAQ - Banana Fish Banana Fish Amino™ Amino14 julho 2024
-
Boruto - Episódio 11: A Sombra Idealizadora, Wiki Naruto14 julho 2024
-
Aluna de 13 anos é campeã de xadrez dos JEAs em Manaus - Portal Em Tempo14 julho 2024
-
Assistir Haikyuu!! 4: To the Top - Episódio 001 Online em HD14 julho 2024